A Multicenter., Rand., Double-Blind, Titration Study to Evaluate & Compare the Efficacy & Safety of Ezetimibe Plus Atorvastatin Vs Atorvastatin in Hypercholesterolemic Pts. at Moderately High Risk for CHD Not Adequately Controlled on Atorvastatin 20 Mg

NCT00276458 Phase 3 COMPLETED Results posted

The purpose of this study is to evaluate and compare the efficacy and safety of ezetimibe plus atorvastatin versus atorvastatin in hypercholesterolemic patients at moderately high risk for coronary heart disease not adequately controlled on atorvastatin 20 mg.

Details

Lead sponsor	Organon and Co
Phase	Phase 3
Status	COMPLETED
Enrolment	196
Start date	2006-02
Completion	2008-01

Conditions

• Hypercholesterolemia

Interventions

• Comparator: atorvastatin
• Comparator: Placebo
• Comparator: ezetimibe
• Comparator: Placebo.

Primary outcomes

• Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6 — 6 weeks
  \[(6 week value - baseline value)/baseline value\]\*100%.